Cover Image
市場調查報告書

陣發性夜間血尿症:開發中產品分析

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 269903
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
陣發性夜間血尿症:開發中產品分析 Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 87 Pages
簡介

陣發性夜間血尿症(血紅素尿症)(PNH)是罕見疾病,病患紅血球較一般更早被破壞。常見有腹痛、腰痛、尿液暗沈、容易出現瘀傷/出血、頭痛、呼吸困難等症狀。致病因素有年齡,肥胖,荷爾蒙療法。治療方法則包含了手術,化療,放射線治療等。

本報告提供陣發性夜間血尿症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

陣發性夜間血尿症概要

治療藥的開發

  • 開發中產品:概要

開發中的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Achillion Pharmaceuticals, Inc.
  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amyndas Pharmaceuticals LLC
  • Apellis Pharmaceuticals Inc
  • Epirus Biopharmaceuticals, Inc.
  • Novartis AG
  • Omeros Corporation
  • Ra Pharmaceuticals, Inc.
  • Regenesance BV
  • The International Biotechnology Center (IBC) Generium

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8449IDB

Summary

Global Markets Direct's, 'Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016', provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria
  • The report reviews pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Paroxysmal Nocturnal Hemoglobinuria therapeutics and enlists all their major and minor projects
  • The report assesses Paroxysmal Nocturnal Hemoglobinuria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Paroxysmal Nocturnal Hemoglobinuria pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Paroxysmal Nocturnal Hemoglobinuria Overview
  • Therapeutics Development
    • Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview
  • Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies
  • Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals, Inc.
    • Akari Therapeutics, Plc
    • Alexion Pharmaceuticals Inc
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • Amyndas Pharmaceuticals LLC
    • Apellis Pharmaceuticals Inc
    • Epirus Biopharmaceuticals, Inc.
    • Novartis AG
    • Omeros Corporation
    • Ra Pharmaceuticals, Inc.
    • Regenesance BV
    • The International Biotechnology Center (IBC) Generium
  • Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACH-4471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-CC5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALXN-1210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMY-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APL-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APL-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Coversin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNR-045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-9405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-906 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101348 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • regenemab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Target Complement C3 for Immunology, PNH and CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tesidolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects
  • Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products
  • Paroxysmal Nocturnal Hemoglobinuria - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2016: Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model
      • Aug 04, 2016: Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System
      • Jul 13, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
      • Jul 12, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
      • Jul 06, 2016: Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin
      • Jun 23, 2016: Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor
      • Jun 10, 2016: Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
      • Jun 10, 2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
      • Jun 10, 2016: Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association
      • Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
      • May 19, 2016: Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
      • May 19, 2016: Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress
      • May 19, 2016: Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated
      • May 19, 2016: Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association
      • May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Akari Therapeutics, Plc, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amgen Inc., H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Novartis AG, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Omeros Corporation, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Regenesance BV, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects, H2 2016
  • Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top